

Key Words: Epigastric soreness, Bernstein test, Cisapride tartrate, Gastroesophageal reflux disease

: , (:135-270)
Tel : (02) 3497-3312, Fax : (02) 3468-3882

Cisapride
non-dopaminergic, non-serotonergic pathway

8 9
.10-14 cisapride

domperidone levosulpiride

가

M. Van Outryve domperidone
metoclopramide
cisapride monohy-
drate

13-73%

가

가

cisapride가

.1 가

.15

.2

levosulpiride

가

domperidone maleate 2

가

.35

cisapride tartrate

.6

가

가

cisapride

levosulpiride, metoclopramide

dompe-

1.

ridone

가

.7

가 , 3():

가 ,

3.

18 , 75

6가 2가

3

levosulpiride cisapride tartrate, domperidone maleate, 2 domperidone maleate(Motilium-M[®]) (DOM) levosulpiride(Levopride[®]) (LEV) 1 3 , 1 10mg 15-30 1 3 , 1 25mg 15-30 . 2

가 가

50% 가

(2) 1

cisapride tartrate(Prepulsid-T[®]) 10mg 2 1 3 , 15-30

4. 가

가

2 가

3

가 . : 75% , : 75% 50%

2. 가 / / , , : 50% 25%

6가 , : 25%

. 0() : , 1() : 가 2 50%

가 가 (2)

, 2() : 가 ,

가 cis-
apride tartrate 2
domperidone maleate levos-
ulpiride 가 (3) :
, 가 , 가
, 가 , 가
, 가 , 가
가 , 가

가 "possible", "pro-
bable", "very likely"
Chi-square test prolactin

가 2
, , , 1.
, 7
가 ,
2 ,
cisapride tartrate 2 prolactin

DOM 149
75 , LEV 74
, , , ,

5.
Intend-to-treatment
categorical data analysis
(1) : ,
domperidone levosulpiride
가 가
, 가
Chi-square test ANOVA
(2) :

가 (Table 1).
가 (Fig.
, Stu- 1) DOM 7.99 ± 2.56 ,
LEV 8.14 ± 2.65

Fig. 1. Symptom scores of the DOM and LEV groups at week 0. There were no statistical differences in 6 dysmotility-like dyspeptic symptoms between the DOM and LEV group at week 0. LEV , levosulpiride ; DOM , domperidone

Table 1. Subject Demographics

	LEV(n=74)	DOM(n=75)	p-value
Age (yr, mean ± S.D)	42.7 ± 11.8	43.0 ± 11.8	0.187
Sex (Female ratio)	77.0%	74.7%	0.736
Sx history (Month, mean ± S.D)	61.1 ± 75.4	58.1 ± 68.7	0.802

LEV, levosulpiride ; DOM, domperidone

2. DOM LEV

2
 DOM 67 (10.7%), LEV
 68 (8.1%) 2 DOM
 LEV

DOM 0.19 ±
 0.54 0.03 ± 0.17

(p=0.019) LEV

0.24 ± 0.66 0.12 ± 0.53

(Fig. 2).

2 DOM 50.8%, LEV 44.1%

DOM LEV 50.0%

DOM

7.39 ± 2.43, 8.44 ± 2.49

(p=0.085)가 LEV

6.83 ± 1.77,

9.11 ± 2.70

(p=0.0001).

가

DOM 8.0% LEV

17.7% 2

(Table 2).

prolactin

LEV 80.0%, DOM 8.3%
 domperidone levosulpiride
 prolactin 가
 가 2

Fig. 2. Comparison of vomiting symptoms in DOM and LEV groups at week 0 and 2.

Only the DOM group showed significant improvement in vomiting(p=0.019).

LEV, levosulpiride ; DOM, domperidone

Table 2. Percentage of Patients Experiencing Adverse Events in Each Treatment Groups

	LEV (n=74)	DOM (n=75)	CIS-T (n=60)
G.I tract	10.9%	8.0%	6.5%
-Epigastric discomfort	2.7%		
-Epigastric soreness	2.7%	4.0%	3.3%
-Abdominal pain			1.7%
-Diarrhea	4.1%	2.7%	1.7%
-Constipation	1.4%		
-Nausea		1.3%	
Endocrine	4.1%	1.3%	0%
-Galactorrhea	2.7%	1.3%	
-Menstruation	1.4%		
Others	2.7%	0%	0%
-Angioedema	1.4%		
-Headache	1.4%		
Total A.E rate (No. of sub.)	17.7% (13/74)	8.0% (6/75)	5.0% (3/60)

LEV, levosulpiride ; DOM, domperidone ; CIS-T, cisapride ; A.E, adverse effect




Fig. 3. Symptom score of nonresponders in the DOM and LEV groups at week 0, 2, and 4. LEV, levosulpiride ; Cis-T, cisapride ; DOM, domperidone

(D1, D2) 2)

domperidone itopride가 . 가 ,
가
levosulpiride

, levosulpiride

가

3) 3

cisapride
dopaminergic, non-serotonergic

Cisapride non-

Table 2.

levosulpiride 17.8%, domperidone
8.0% levosulpiride 2

.15

prolactin
DOM LEV prolactin

II

prolactin 가
2

가

가

(D1, D2)

levosulpiride
domperidone maleate 2
가

levosulpiride가 prolactin 가
1
18 가

lev-

cisapride tartrate
가

osulpiride
Cisapride tartrate
가

75.0% 73.3%

ate levosulpiride 2 domperidone mal-

.15, 19.20

5.0% domperidone levosulpiride
D2

, 2 DOM LEV
50.8% 44.1%

가

50%

domperidone levosul-

levosulpiride domperidone ipride

(p=0.0001)

가 cisapride tartrate 75.0%

73.3% . cisapride tartrate

5.0%

:

domperidone maleate

levosulpiride

가 ,

:

levosulpiride levosulpiride prolactin 가

domperidone

domperidone mealate

가 ,

cisapride tartrate cisapride tartrate가

가

: 7

149

domperidone maleate 1 30mg

levosulpiride 1 75mg

2

가

2

cisapride tartrate

1 30mg 2

가

: Domperidone maleate (DOM)

levosulpiride (LEV)

,

,

,

가

.

2 DOM LEV

50.8% 44.1%

DOM

8.0% LEV 2

17.7% prolactin

LEV DOM

10

(80.0% vs 8.3%). Cisapride tartrate

1. , . 1999:139-157
2. Robert SF, Henry PP. Management of nonulcer dyspepsia. NEJM 1998;339:1376-1381.
3. Camilleri M, Malagedala JR, Kao PL, et al. Gastric and autonomic responses to stress in functional dyspepsia. Dig Dis Sci 1986;31:1169-1177.
4. Labo G, Bortolotti M, Vezzadini P, et al. Interdigestive gastroduodenal motility and serum motilin in patients with idiopathic delay in gastric emptying. Gastroenterol 1986;90:20-26.
5. Rees WDW, Miller LJ, Malagedala JR. Dyspepsia, antral motor dysfunction and gastric stasis of solids. Gastroenterol 1980;78:360-365.
6. , , . 1998;4:1-12.
7. , , , , . Levosulpiride 1997;40:30-36.

8. Testoni PA, Bagnolo F, Fanti L, et al. Effect of long-term oral therapy with cisapride on the inter-digestive antro-duodenal motility pattern in dyspeptic subjects. *Curr Ther Res* 1988;43:1118-1125.
 9. Corinaldese R, Raiti C, Stanghellini V, et al. Comparative effects of oral cisapride and metoclopramide on gastric emptying of solids and symptoms in patients with functional dyspepsia and gastroparesis. *Curr Ther Res* 1987;42:428-435.
 10. Abell TL, Camilleri M, DiMagno EP, et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. *Dig Dis Sci* 1990; 36:616-620.
 11. Deruyttere M, Milo R, Creytens G, et al. Therapy of chronic functional dyspepsia: multicentre cross-over study of cisapride and placebo. *Progr Med* 1987;43:61-75.
 12. Francois I, De Nutte N, Hannon R. Cisapride in the treatment of non-ulcer dyspepsia. *Progr Med* 1987;43:83-89.
 13. Rosch W. Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. *Scand J Gastroenterol* 1987;43:61-75.
 14. Verlinden M. Dose-finding of cisapride in non-ulcer dyspepsia. *Gastroenterol* 1990;28 Suppl I: 31-35.
 15. M. Van Outryve, N. De Nutte, P. Van Eeghem, et al. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide : A double-blind, place-controlled study. *Proceedings of a symposium: Round table on dyspepsia* 1992.
 16. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. *Gut* 1999; 34(suppl 2):38-44.
 17. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. *Gut* 1999; 45 Suppl II:37-42.
 18. M. Van Outryve, N. De Nutte, P. Van Eeghem, et al. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide : A double-blind, place-controlled study. *Proceedings of a symposium: Round table on dyspepsia* 1992.
 19. Kahrilas PJ. Cigarette smoking and gastroesophageal reflux disease. *Dig Dis Sci* 1992;10:61-71.
 20. Ho KY, Kang JY, Seo WA. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. *Am J Gastroenterol* 1998;93:1816-1822.
-

-

-

가

Helicobacter pylori
